Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM42KZW)

Drug Name

DS-1093 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Anemia	3A00-3A9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting HIF-prolyl hydroxylase (HPH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclopirox	DMN5T2A	Cutaneous candidiasis	1F23.14	Approved	[3]
AKB-6548	DM2EJM3	Anaemia	3A90	Phase 3	[4]
JTZ-951	DM8FSPV	Anaemia	3A90	Phase 3	[5]
BAY 853934	DM407I6	Anaemia	3A90	Phase 3	[6]
FG-2216	DM7RYL4	Kidney disease	GC2Z	Phase 2	[7]
ZYAN1	DM796RI	Anaemia	3A90	Phase 1	[8]
JNJ-42905343	DMCNBHY	Anaemia	3A90	Preclinical	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT02299661) Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease. U.S. National Institutes of Health.
2	Company report (Daiichisankyo)
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	DOI: 10.1038/nrd4422
5	DOI: 10.1038/nrneph.2015.82
6	Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem. 2018 May 23;13(10):988-1003.
7	Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
8	Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Drug Res (Stuttg). 2016 Feb;66(2):107-12.
9	Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015 Aug;172(16):4078-88.